News - Page 3 of 4 - Mitsui & Co. Global Investment, Inc.

Valens Semiconductor, Ltd. (“Valens”), a premier provider of high-speed connectivity solutions for the audio-video and automotive markets, announced today that the registration statement on Form F-4 (as amended, the “Registration Statement”) related to the previously announced business combination (the “Business Combination”) with PTK Acquisition Corp. (NYSE: PTK) (“PTK”), a special purpose acquisition company, has been declared effective by the Securities and Exchange Commission (“SEC”).

News|Rallybio

RallyBio goes public.

By Mswartz

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced the closing of its initial public offering of 7,130,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 930,000 additional shares of common stock, at a public offering price of $13.00 per share.

News|Rallybio

RallyBio announces clinical proof of concept for RLYB211, an anti-HPA-1a antibody for the prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT).

By Mswartz

Rallybio, a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced that clinical proof of concept has been established in the ongoing Phase 1/2 study of RLYB211.

News|Proterra

Proterra goes public on NASDAQ through SPAC (special purpose acquisition company) merger.

By Mswartz

Proterra Inc (“Proterra” or the “Company”), a leading innovator in commercial vehicle electrification technology, today announced that its shares of common stock and warrants will begin trading on the Nasdaq Global Select Market today under the new ticker symbols “PTRA” and “PTRAW,” respectively.

News|Svante

Svante receives $25M from the Government of Canada to support the commercialization and industrialization of their low-cost carbon capture technology.

By Mswartz

Svante Inc., announced that the Government of Canada made a CDN$25 million investment to support the industrialization and commercialization of its novel low-cost carbon capture technology within the North American market.

Valens completes Form F-4 registration in preparation of SPAC merger with PTK Acquisition Corp.

RallyBio goes public.

RallyBio announces clinical proof of concept for RLYB211, an anti-HPA-1a antibody for the prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT).

Proterra goes public on NASDAQ through SPAC (special purpose acquisition company) merger.

Svante receives $25M from the Government of Canada to support the commercialization and industrialization of their low-cost carbon capture technology.